Chronic Kidney Disease Management - USMLE Step 3

SECTION 1

Historical Context & Motivation

The recognition of chronic kidney disease (CKD) as a major public health problem evolved gradually over more than a century. Early nephrology focused almost exclusively on acute presentations such as glomerulonephritis and nephrotic syndrome, while the slow, insidious decline of renal function was often overlooked until patients presented with overt uremia requiring dialysis. It was not until clinicians developed reliable methods for estimating kidney function — and large epidemiological studies revealed the staggering prevalence of subclinical renal impairment — that the field shifted toward proactive, stage-based management. Today, CKD affects approximately 15% of the U.S. adult population, imposes an enormous burden of cardiovascular morbidity, and represents one of the fastest-growing causes of mortality worldwide.

1950s • Advent of Hemodialysis

Willem Kolff's pioneering work on the artificial kidney during World War II led to the first chronic hemodialysis programs, transforming end-stage renal disease from a death sentence into a treatable condition and drawing clinical attention to the trajectory of progressive kidney failure.

1976 • Cockcroft-Gault Equation

Donald Cockcroft and Henry Gault published the first widely adopted formula for estimating creatinine clearance from serum creatinine, age, weight, and sex — enabling clinicians to quantify renal function without cumbersome 24-hour urine collections.

1999 • MDRD Study & eGFR

The Modification of Diet in Renal Disease (MDRD) study equation provided a practical estimated glomerular filtration rate (eGFR) that could be automatically reported by clinical laboratories, catalyzing early detection and surveillance of CKD at scale.

2002 • KDOQI Guidelines & CKD Staging

The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) established the now-familiar five-stage classification of CKD based on eGFR, creating a common language for clinicians, researchers, and public health agencies.

2020s • SGLT2 Inhibitors & Novel Therapies

Landmark trials such as DAPA-CKD and EMPA-KIDNEY demonstrated that SGLT2 inhibitors slow CKD progression in both diabetic and non-diabetic patients, ushering in a new era of disease-modifying therapy alongside traditional RAAS blockade.

The central question driving modern CKD management is straightforward yet clinically demanding: how can we identify patients early, slow the relentless loss of nephrons, mitigate the systemic complications of declining renal function — including cardiovascular disease, metabolic bone disease, anemia, and electrolyte derangements — and optimally prepare patients for renal replacement therapy when it becomes necessary? This lesson addresses each of these domains systematically.

SECTION 2

Core Principles of CKD Management

Effective CKD management rests on a set of interconnected principles that span early identification, risk-factor modification, complication prevention, and timely referral. Rather than a single therapeutic intervention, CKD care is an integrated, multidisciplinary strategy whose components must be tailored to the patient's stage of disease, comorbidities, and trajectory of GFR decline. The following foundational concepts underpin every clinical decision in this domain.

Stage-Based Classification

CKD is classified into stages 1–5 based on eGFR (mL/min/1.73 m²) and the presence of kidney damage markers such as albuminuria. Staging determines surveillance intervals, therapeutic thresholds, and referral timing.

RAAS Blockade

Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) reduce intraglomerular pressure, diminish proteinuria, and slow progression. They remain first-line therapy for proteinuric CKD regardless of etiology.

Glycemic & Blood Pressure Control

In diabetic CKD, targeting an HbA1c < 7% (individualized) reduces microvascular damage. Blood pressure targets of < 130/80 mmHg — or < 120 systolic for high-risk patients — mitigate both renal and cardiovascular risk.

SGLT2 Inhibitor Therapy

Sodium-glucose cotransporter 2 (SGLT2) inhibitors activate tubuloglomerular feedback, reduce hyperfiltration, and confer nephroprotection beyond their glucose-lowering effects. Current guidelines recommend them for CKD patients with eGFR ≥ 20 mL/min/1.73 m².

Complication Management

As eGFR declines, complications including anemia (erythropoietin deficiency), CKD-mineral bone disease (secondary hyperparathyroidism), metabolic acidosis, and hyperkalemia must be anticipated and treated proactively to reduce morbidity and mortality.

✦

KEY TAKEAWAY

Think of the kidney as a dam with thousands of tiny sluice gates (nephrons). As gates fail, the remaining ones open wider (hyperfiltration) to compensate — temporarily maintaining flow but accelerating wear. RAAS blockade and SGLT2 inhibitors effectively reduce the pressure on each remaining gate, extending the dam's functional lifespan. Every other CKD intervention — blood pressure control, glycemic management, metabolic correction — serves to reduce the environmental stressors that damage the gates in the first place.

SECTION 3

CKD Staging & Progression — Visual Overview

The five stages of CKD are defined by progressively declining eGFR ranges. Stages 1 and 2 require evidence of kidney damage (e.g., albuminuria, structural abnormalities) because eGFR alone may be normal or near-normal. The color gradient from green (low risk) to red (very high risk) reflects the exponential increase in cardiovascular and mortality risk with advancing stage.

The diagram above illustrates the stage-based framework that anchors all subsequent management decisions. Notice that stages 1 and 2 require the presence of structural or functional kidney damage markers — most commonly albuminuria (albumin-to-creatinine ratio ≥ 30 mg/g) — because an eGFR ≥ 60 mL/min/1.73 m² alone does not confirm CKD. The KDIGO 2012 guidelines further subdivide stage 3 into 3a (eGFR 45–59) and 3b (eGFR 30–44) to reflect the clinically significant difference in complication burden and progression risk between these subgroups. Additionally, the albuminuria category (A1: < 30, A2: 30–300, A3: > 300 mg/g) functions as an independent prognostic axis. A patient in stage 2 with A3 albuminuria may carry a higher risk of progression and cardiovascular events than a patient in stage 3a with A1 albuminuria, underscoring the importance of evaluating both axes simultaneously.

SECTION 4

Pathophysiology & Therapeutic Mechanisms

CKD progression is fundamentally driven by a vicious cycle of nephron loss, compensatory hyperfiltration, glomerular hypertension, and progressive fibrosis. Understanding this cycle is essential for appreciating why specific pharmacologic interventions are disease-modifying rather than merely symptomatic.

Glomerular Hyperfiltration & the Maladaptive Response

When nephrons are lost to any initial insult — diabetic glomerulosclerosis, hypertensive nephrosclerosis, or immune-mediated injury — the remaining functional nephrons increase their single-nephron GFR to maintain overall kidney function. This compensatory hyperfiltration occurs via dilation of the afferent arteriole and constriction of the efferent arteriole (mediated in part by angiotensin II), raising intraglomerular capillary pressure. While this preserves whole-kidney GFR in the short term, the elevated pressure damages the glomerular basement membrane, promotes podocyte injury, and accelerates mesangial expansion — leading to progressive glomerulosclerosis and further nephron loss. The renin-angiotensin-aldosterone system (RAAS) is a central mediator of this maladaptive response, which is why RAAS blockade is the cornerstone of renoprotective therapy.

Mechanism of ACEi/ARB Renoprotection

ACE inhibitors and ARBs lower intraglomerular pressure primarily by blocking angiotensin II-mediated efferent arteriolar vasoconstriction. This reduces the transglomerular pressure gradient, decreases proteinuria (itself a driver of tubulointerstitial inflammation and fibrosis), and attenuates the profibrotic signaling of angiotensin II on mesangial cells and fibroblasts. An initial dip in eGFR of up to 30% after ACEi/ARB initiation is hemodynamically expected and acceptable; it reflects reduced hyperfiltration rather than parenchymal damage. The medication should be continued unless eGFR falls more than 30% or hyperkalemia becomes refractory.

Mechanism of SGLT2 Inhibitor Renoprotection

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) block the sodium-glucose cotransporter 2 in the proximal tubule, increasing sodium delivery to the macula densa. This restores tubuloglomerular feedback (TGF), causing afferent arteriolar vasoconstriction and reducing single-nephron GFR — the mirror-image complement to ACEi/ARB-mediated efferent dilation. Additional mechanisms include reduction of tubular oxygen consumption, attenuation of tubulointerstitial inflammation, natriuresis-mediated blood pressure reduction, and possible anti-fibrotic effects. Like ACEi/ARBs, SGLT2 inhibitors produce an initial eGFR dip that stabilizes within weeks and predicts long-term nephroprotection.

CKD-EPI 2021 EQUATION (RACE-FREE)

eGFR = 142 × min(Scr/κ, 1)^α × max(Scr/κ, 1)^(−1.200) × 0.9938^Age × (1.012 if female)

Where Scr = serum creatinine (mg/dL), κ = 0.7 (female) or 0.9 (male), α = −0.241 (female) or −0.302 (male). This 2021 revision eliminated the race coefficient to improve equity while maintaining predictive accuracy.

FRACTIONAL EXCRETION OF SODIUM (FENa)

FENa (%) = (UNa × PCr) / (PNa × UCr) × 100

FENa helps differentiate prerenal from intrinsic renal causes of AKI superimposed on CKD. A FENa < 1% suggests prerenal physiology (volume depletion, heart failure), while > 2% suggests intrinsic tubular damage. This distinction is critical in CKD patients who present with acute decompensation.

SECTION 5

Complication Management by CKD Stage

As GFR declines, the kidney's capacity to maintain homeostasis diminishes across multiple metabolic axes. Effective CKD management requires anticipating these complications before they become clinically overt, with specific interventions keyed to the patient's stage. The following diagram and table provide a systematic framework for complication surveillance and treatment.

This cascade diagram illustrates the sequential emergence of CKD complications as eGFR declines. Cardiovascular risk is present from the earliest stages, while complications such as CKD-mineral bone disease and metabolic acidosis typically emerge at eGFR < 45 and < 30, respectively. Proactive monitoring should begin at least one stage before the expected onset.

Complication	Onset (eGFR)	Key Interventions	Targets / Monitoring
Anemia	< 60 mL/min	Iron repletion (IV preferred in CKD 3b–5); ESAs when Hb < 10 g/dL after iron optimization	Hb target 10–11.5 g/dL; avoid > 13 g/dL (thrombosis risk). TSAT > 30%, ferritin > 500 ng/mL for dialysis patients.
CKD-MBD	< 45 mL/min	Phosphate binders (sevelamer, calcium acetate); calcitriol or active vitamin D analogs; calcimimetics (cinacalcet) for dialysis patients	PO₄ 2.5–4.5 mg/dL; PTH within 2–9× upper normal for CKD 5D. Correct 25-OH vitamin D deficiency.
Metabolic Acidosis	< 30 mL/min	Oral NaHCO₃ supplementation (typically 650–1300 mg TID); dietary counseling to increase fruit and vegetable intake	Serum HCO₃ ≥ 22 mEq/L. Acidosis accelerates muscle wasting, bone disease, and CKD progression.
Hyperkalemia	< 30 mL/min	Dietary K⁺ restriction; potassium binders (patiromer, sodium zirconium cyclosilicate); adjust RAAS blockers if refractory	Serum K⁺ < 5.5 mEq/L. Do NOT reflexively discontinue ACEi/ARB — use binders to enable continued RAAS blockade.
Volume Overload	< 30 mL/min	Dietary sodium restriction (< 2 g/day); loop diuretics (furosemide, bumetanide) — often at high doses in advanced CKD	Daily weights; avoid thiazide monotherapy when eGFR < 30 (insufficient distal delivery).

Key CKD Complications and Stage-Specific Management

SECTION 6

Worked Example — Managing a CKD Patient

Consider a 58-year-old woman with type 2 diabetes, hypertension, and a recent serum creatinine of 1.8 mg/dL. Her urine albumin-to-creatinine ratio (UACR) is 480 mg/g. She is currently on metformin 1000 mg BID, amlodipine 10 mg, and hydrochlorothiazide 25 mg. Her HbA1c is 7.8%, blood pressure is 148/92 mmHg, hemoglobin is 10.8 g/dL, potassium is 4.6 mEq/L, bicarbonate is 20 mEq/L, and phosphorus is 5.2 mg/dL.

Comprehensive CKD Management Plan

1
Step 1 — Estimate GFR & Stage the Disease

Using the CKD-EPI 2021 equation with Scr = 1.8 mg/dL, female sex (κ = 0.7, α = −0.241), and age 58: since Scr/κ = 1.8/0.7 = 2.57 > 1, we use the max term. eGFR = 142 × $1^{−0.241}$ × $2.57^{−1.200}$ × $0.9938^{58}$ × 1.012. Calculating: $2.57^{−1.200}$ ≈ 0.328; $0.9938^{58}$ ≈ 0.696; 142 × 1 × 0.328 × 0.696 × 1.012 ≈ 32.8 mL/min/1.73 m². With UACR of 480 mg/g (category A3), this patient has CKD stage 3b, A3 — placing her in the 'very high risk' category for progression and cardiovascular events.

CKD Stage 3b, A3 (very high risk)
2
Step 2 — Initiate RAAS Blockade

This patient has proteinuric diabetic kidney disease and is not on an ACEi or ARB — a critical gap. Start lisinopril 10 mg daily (or losartan 50 mg) and titrate to the maximum tolerated dose. Recheck serum creatinine and potassium within 1–2 weeks. An eGFR drop up to 30% is acceptable. This intervention also addresses the uncontrolled hypertension (target < 130/80 mmHg).

ACEi initiated; plan to titrate to max dose with K⁺/Cr monitoring
3
Step 3 — Add SGLT2 Inhibitor

With eGFR ≈ 33 mL/min (≥ 20), she qualifies for SGLT2 inhibitor therapy. Start dapagliflozin 10 mg daily or empagliflozin 10 mg daily. Counsel regarding genital mycotic infections and the expected initial eGFR dip. The SGLT2 inhibitor will also improve glycemic control (allowing potential metformin dose adjustment), reduce blood pressure by 3–5 mmHg, and provide independent cardiovascular protection.

Dapagliflozin 10 mg added for nephroprotection + glycemic benefit
4
Step 4 — Address Metabolic Complications

Bicarbonate of 20 mEq/L (< 22) warrants oral sodium bicarbonate 650 mg TID. Phosphorus of 5.2 mg/dL (elevated) necessitates dietary phosphate restriction and likely sevelamer 800 mg TID with meals. Check PTH and 25-OH vitamin D — secondary hyperparathyroidism is likely developing at this eGFR. Hemoglobin of 10.8 g/dL is borderline; check iron studies (TSAT and ferritin) before considering erythropoiesis-stimulating agents.

NaHCO₃ and sevelamer started; PTH, vitamin D, and iron studies ordered
5
Step 5 — Optimize BP & Glycemia; Plan Follow-Up

Replace hydrochlorothiazide (less effective at eGFR < 30) with a loop diuretic if volume overload is present, or discontinue if euvolemic. The combination of ACEi + SGLT2 inhibitor + amlodipine should improve BP toward goal. For glycemia (HbA1c 7.8%), the SGLT2 inhibitor addition and metformin dose adjustment (maximum metformin dose at eGFR 30–44 is 1000 mg/day per FDA guidance) should help. Reassess HbA1c in 3 months. Refer to nephrology given stage 3b with very high risk profile. Discuss eventual renal replacement therapy options (including preemptive transplant evaluation) at the next visit.

Diuretic swap; metformin reduced to 1000 mg/day; nephrology referral placed

SECTION 7

Pharmacologic Comparisons & Limitations

Modern CKD management employs multiple pharmacologic classes with complementary mechanisms. Understanding their relative strengths, limitations, and important caveats is essential for optimal prescribing — particularly when USMLE Step 3 questions test nuanced management decisions such as when to continue versus discontinue RAAS blockade or which patients are candidates for SGLT2 inhibitors.

Agent Class	Strengths	Limitations / Risks
ACEi / ARBs	Gold standard for proteinuric CKD; reduce CV events; slow progression in both diabetic and non-diabetic CKD; well-established evidence base (RENAAL, IDNT, REIN)	Hyperkalemia; acute eGFR drop (acceptable up to 30%); contraindicated in bilateral renal artery stenosis and pregnancy; do NOT combine ACEi + ARB (ONTARGET — increased adverse events without benefit)
SGLT2 Inhibitors	Nephroprotective via TGF restoration; CV benefit (reduced heart failure hospitalization); effective regardless of diabetes status; once-daily dosing; weight and BP reduction	Genital mycotic infections; euglycemic DKA risk (rare, mainly in type 1 DM); avoid initiation if eGFR < 20; limited long-term data beyond 5 years; volume depletion in frail elderly
Finerenone (nsMRA)	Non-steroidal MRA with anti-inflammatory/anti-fibrotic renal effects; proven to reduce CKD progression and CV events in diabetic CKD (FIDELIO-DKD, FIGARO-DKD)	Hyperkalemia (requires close K⁺ monitoring); currently FDA-approved only for diabetic CKD; less experience in non-diabetic populations; must be used in combination with maximized RAAS blockade
ESAs (epoetin, darbepoetin)	Effective for symptomatic anemia; reduce transfusion requirements; improve quality of life	Targeting Hb > 13 g/dL increases stroke, thrombosis, and mortality (TREAT, CREATE trials); hypertension exacerbation; pure red cell aplasia (rare); must optimize iron stores first
Phosphate Binders	Control hyperphosphatemia; sevelamer may reduce vascular calcification compared to calcium-based binders; improve CKD-MBD control	Pill burden (multiple tablets with every meal); GI side effects (nausea, constipation); calcium-based binders may worsen vascular calcification; cost of newer agents (sucroferric oxyhydroxide, lanthanum)

Pharmacologic Classes in CKD: Benefits vs. Risks

✦

KEY TAKEAWAY

Think of CKD pharmacotherapy as a layered defense system, analogous to redundant safety systems in aerospace engineering. ACEi/ARBs form the primary shield (efferent arteriolar dilation), SGLT2 inhibitors add a second independent layer (afferent arteriolar constriction via TGF), and finerenone provides a third anti-fibrotic/anti-inflammatory layer. Each system protects through a different mechanism, and combined, they offer synergistic nephroprotection that no single agent can achieve alone. The key clinical skill is maximizing these layers while vigilantly monitoring for hyperkalemia and acute eGFR changes.

SECTION 8

Dialysis Preparation & Transplant Considerations

While the primary goal of CKD management is to delay progression, many patients will ultimately require renal replacement therapy (RRT). Timely preparation — including vascular access creation, transplant evaluation, and patient education — dramatically impacts outcomes. For USMLE Step 3 purposes, understanding the thresholds and logistics of RRT initiation is a high-yield topic.

Domain	Conservative CKD Management	Renal Replacement Therapy
Indications	eGFR > 15 mL/min without uremic symptoms; patient preference with advanced age/comorbidities	Symptomatic uremia (encephalopathy, pericarditis, nausea); refractory volume overload, hyperkalemia, or acidosis; eGFR < 5–10 mL/min typically
Preparation Timeline	Ongoing medication optimization, dietary counseling, complication management, nephrology co-management	AV fistula creation at eGFR ~20–25 (6 months to mature); PD catheter 2–4 weeks prior; transplant evaluation ideally begins at eGFR < 20
Mortality Benefit	RAAS blockade + SGLT2i reduce CV mortality and slow progression; lifestyle modifications additive	Transplant > PD ≈ HD for long-term survival; preemptive transplant (before dialysis initiation) confers best outcomes
Drug Adjustments	Dose-reduce renally cleared drugs; avoid nephrotoxins (NSAIDs, aminoglycosides, IV contrast without preparation)	Dialyzability of drugs must be considered; ESA dosing may increase; phosphate binders often escalated; ACEi/ARBs may continue on dialysis
Key Trials	DAPA-CKD, EMPA-KIDNEY, FIDELIO-DKD, SPRINT, ACCORD	IDEAL (early vs. late dialysis start — no benefit to early initiation based on eGFR alone)

Conservative Management vs. Renal Replacement Therapy

⚠

HIGH-YIELD FOR STEP 3

The IDEAL trial demonstrated that initiating dialysis at eGFR 10–14 (early) versus 5–7 (late) mL/min showed no survival benefit. Current practice favors symptom-based rather than eGFR-based dialysis initiation. The absolute indications for urgent dialysis can be remembered with the mnemonic AEIOU: Acidosis (refractory), Electrolyte imbalance (hyperkalemia), Ingestion (toxic alcohols, lithium), Overload (volume), and Uremic symptoms (pericarditis, encephalopathy, bleeding).

Looking ahead, the CKD treatment landscape continues to evolve rapidly. Endothelin receptor antagonists (atrasentan), HIF-prolyl hydroxylase inhibitors (roxadustat) for anemia, and novel anti-fibrotic agents are in various stages of clinical development. The integration of these agents into the existing layered pharmacotherapy framework will likely define the next generation of CKD management guidelines.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

A 62-year-old man with CKD stage 3a (eGFR 52) and type 2 diabetes is started on lisinopril 20 mg daily. Two weeks later, his serum creatinine rises from 1.4 to 1.7 mg/dL and his eGFR drops to 42 mL/min. His potassium is 5.1 mEq/L. What is the most appropriate next step in management?

Show answer

The eGFR drop from 52 to 42 represents approximately a 19% decline, which is within the acceptable hemodynamic range (< 30%) expected after ACEi initiation. This reflects beneficial reduction in intraglomerular hyperfiltration rather than parenchymal injury. The potassium of 5.1 is mildly elevated but manageable. The correct answer is to continue lisinopril at the current dose and recheck labs in 2–4 weeks. Discontinuing the ACEi would remove the nephroprotective benefit. Only if eGFR drops > 30% or K⁺ exceeds 5.5 mEq/L despite dietary modification should dose reduction or discontinuation be considered.

Question 2: BASIC CALCULATION

A 70-year-old woman has a serum creatinine of 1.5 mg/dL. Using the CKD-EPI 2021 equation (female: κ = 0.7, α = −0.241), estimate her eGFR. Scr/κ = 2.14 > 1, so use: eGFR = 142 × (Scr/κ)^(−1.200) × 0.9938^Age × 1.012. What CKD stage does this correspond to, and what albuminuria testing should be ordered?

Show answer

Calculating: Scr/κ = 1.5/0.7 = 2.14. Then

2.14^{−1.200}

≈ 0.404. The age factor:

0.9938^{70}

≈ 0.649. Multiplying: 142 × 0.404 × 0.649 × 1.012 ≈ 37.7 mL/min/1.73 m². This places her in CKD stage 3b (eGFR 30–44). A urine albumin-to-creatinine ratio (UACR) on a spot morning specimen should be ordered to fully classify her risk (A1, A2, or A3). If UACR ≥ 30 mg/g, RAAS blockade should be initiated; regardless, SGLT2 inhibitor therapy is indicated at this eGFR.

Question 3: INTERMEDIATE

A 55-year-old man with CKD stage 4 (eGFR 22), type 2 diabetes, and heart failure with reduced ejection fraction is on maximum-dose losartan, dapagliflozin, metoprolol, and furosemide. His labs show K⁺ 5.8 mEq/L, HCO₃ 18 mEq/L, Hb 9.2 g/dL, and PO₄ 6.1 mg/dL. Prioritize the management of his metabolic derangements and describe the key trade-offs involved.

Show answer

The most urgent issue is the hyperkalemia (K⁺ 5.8) because it carries immediate cardiac risk. However, rather than discontinuing the nephroprotective losartan, initiate patiromer or sodium zirconium cyclosilicate to enable continued RAAS blockade. Next, address metabolic acidosis (HCO₃ 18) with oral NaHCO₃ — correcting acidosis itself helps lower K⁺ by promoting intracellular shift. Start a phosphate binder (sevelamer preferred over calcium-based given CKD-MBD risk) for PO₄ 6.1. For anemia (Hb 9.2), check iron studies; if TSAT < 20% or ferritin < 100 ng/mL, give IV iron first. If Hb remains < 10 after iron repletion, consider an ESA with a target of 10–11.5 g/dL. The key trade-off is maintaining maximal cardioprotective/nephroprotective medications (losartan + dapagliflozin) while managing their K⁺-elevating effects.

Question 4: APPLIED

A 48-year-old woman with IgA nephropathy, CKD stage 3a (eGFR 55), persistent proteinuria of 1.8 g/day despite maximal-dose ramipril, and a blood pressure of 128/78 mmHg asks about additional therapies to slow progression. She has no diabetes. Outline a comprehensive evidence-based plan, including the rationale for each intervention.

Show answer

Despite maximal ACEi, persistent heavy proteinuria (> 1 g/day) indicates ongoing nephron injury and high progression risk. First, add an SGLT2 inhibitor (e.g., dapagliflozin 10 mg); the DAPA-CKD trial demonstrated nephroprotection regardless of diabetes status, and SGLT2 inhibitors reduce proteinuria by 30–40% on top of RAAS blockade. Second, ensure strict sodium restriction (< 2 g/day) because high sodium intake blunts ACEi antiproteinuric efficacy. Third, consider immunosuppressive therapy for IgA nephropathy: the TESTING trial showed low-dose methylprednisolone reduces proteinuria and slows eGFR decline in high-risk IgA nephropathy patients, though infection risk must be weighed. Newer targeted therapies such as sparsentan (dual endothelin/angiotensin receptor antagonist, FDA-approved for IgA nephropathy) offer an additional proteinuria reduction mechanism. BP is at goal. Avoid NSAIDs strictly. Monitor eGFR and proteinuria every 3 months.

Question 5: CRITICAL THINKING

A debate exists about whether CKD patients with eGFR 20–30 mL/min and persistent hyperkalemia (K⁺ 5.5–6.0 mEq/L) despite dietary modification should have their ACEi/ARB dose reduced (accepting loss of nephroprotection) or should receive chronic potassium binders (accepting pill burden, cost, and possible GI side effects). Using evidence from landmark trials, argue for one approach and identify the conditions under which you would switch strategies.

Show answer

The evidence strongly favors maintaining maximal RAAS blockade with the addition of potassium binders. The RENAAL, IDNT, and REIN trials collectively demonstrated that ACEi/ARB therapy reduces the relative risk of CKD progression by 20–30% and significantly decreases proteinuria, a surrogate for renal injury. Discontinuing or reducing these agents for K⁺ management sacrifices a proven disease-modifying benefit to avoid a manageable side effect. Modern potassium binders — patiromer (OPAL-HK trial) and sodium zirconium cyclosilicate (HARMONIZE trial) — are well-tolerated, effective within hours, and enable sustained RAAS blockade in > 90% of patients. However, switching strategies is warranted when: (1) K⁺ exceeds 6.0 mEq/L despite maximal binder therapy, (2) the patient develops ECG changes (peaked T waves, widened QRS), (3) intercurrent illness (AKI, volume depletion) superimposes additional hyperkalemia risk, or (4) the patient cannot tolerate or afford binder therapy. In such cases, a stepwise ACEi/ARB dose reduction (not complete cessation) is preferred, with close monitoring and resumption once K⁺ is controlled.

SUMMARY

Chronic Kidney Disease Management — Summary

Summary

Chronic kidney disease management is a stage-based, multidisciplinary strategy built on the KDIGO classification system (stages 1–5 by eGFR, categories A1–A3 by albuminuria). The cornerstone pharmacologic interventions are ACEi/ARB therapy (which reduces intraglomerular pressure via efferent arteriolar dilation) and SGLT2 inhibitors (which restore tubuloglomerular feedback and reduce hyperfiltration via afferent arteriolar constriction). Together with finerenone for diabetic CKD, these agents form a layered nephroprotective regimen. An initial eGFR dip of up to 30% after ACEi/ARB initiation or SGLT2 inhibitor start is hemodynamically expected and should not prompt discontinuation.

As eGFR declines below 60 mL/min, complications emerge in a predictable cascade: cardiovascular disease (the leading cause of death at every CKD stage), anemia (target Hb 10–11.5 g/dL with iron-first approach), CKD-mineral bone disease (phosphate binders, vitamin D, calcimimetics), metabolic acidosis (oral NaHCO₃ to maintain HCO₃ ≥ 22), and hyperkalemia (potassium binders to enable continued RAAS blockade). Dialysis initiation should be guided by symptoms (AEIOU mnemonic) rather than an arbitrary eGFR threshold. AV fistula creation should begin at eGFR ~20–25 to allow maturation time, and transplant evaluation should be pursued early for eligible patients, as preemptive transplantation offers the best long-term survival.